Patrick Holt: Thanks very much for your question. Really appreciate that. So firstly, to the question around exclusives, typically, they are annual contracts. And it’s really in January that we have absolute clarity on those contracts being renewed. Right now, they represent about 75% of our business, and that’s continued to be stable for a significant period of time. As we sit here in October, we are feeling that we have good progress as we enter in 2024, feeling very comfortable. We certainly have seen some signals around this time of the year that really give us confidence as we’re entering 2024. With that said, we get absolute line of sight on our exclusive contracts in January. But that’s been a really stable and important part of the business.
That continues to be the uber focus of the US focus that we can — at the US, as we continue to invest in trade and managed care capabilities. To the UK question, I think it possibly — you may have misheard me. I think it’s 1,000 patients that we have so far on therapy in the UK that we estimate. And as I mentioned, we’ve demonstrated 30% quarter-over-quarter pharmacy sales which, let’s be honest, it’s still not where we need to be in the UK, but I think as a result of the leadership changes that we’ve seen, and we’re starting to see some focus with really a focus on key accounts.
Unidentified Analyst: Okay. Thanks.
Operator: Your next question is coming from Roanna Ruiz at Leerink.
Roanna Ruiz: Hey. Morning everyone. So on the Medicaid rebate adjustment of about $6.5 million, I was curious, could that occur in future quarters to the same degree and what’s driving that adjustment? And second question is regarding your amended supplier agreements, how close are you to completing this process? And could you just explain why amending these agreements had a bit of a higher charge this year relative to last year?
Tom Reilly: Sure, Roanna. It’s Tom. I can take both those questions. So the first question relates to the Medicaid adjustment component. So in the quarter, correct, we did recognize the $6.5 million one-time Medicaid adjustment. So it is one-time. We don’t expect that moving forward. The reason for the adjustment is we provided an estimate of how many patients were coming through the Medicaid channel as revenue. And actually the patients were lower. So this quarter we did recognize that true-up, but it is a one-time component. So the second question, Ron, related to supply agreements and line of sight on the supply agreements. I think overall, the position here is we have a really good relationship with our suppliers and we’re making progress in balancing our supply commitments with future demands that we need.
So overall, it’s hard to determine when we expect these restructuring charges to end. We’re balancing our commitments with the suppliers versus the commercial sales pickup. And it is complicated because as part of our supply negotiations, we need to make supply purchases in order to ensure we have future supply to meet the potential demand for the EU and outside of the US. So overall, we’re making good progress. We’re balancing it with the suppliers. But we really need to see EU sales to pick up to see when the overall charges will stop.
Roanna Ruiz: Okay, got it. Thanks.
Operator: Your next question is coming from Paul Choi with Goldman Sachs.
Unidentified Analyst: Hi, this is [Khalil] (ph) calling in for Paul. Thanks for taking our questions. I suppose I’ll ask a question about ex-US. So thanks for giving the color on the Netherlands and the Spain launches. I was wondering where those were good proxies for what you expect to see in China or whether your recent launches in Kuwait and Saudi Arabia would be a more easy lateral for that.
